Miyatani Tomohiko, Kurita Nobuhiro, Mikami Chie, Kashihara Hideya, Higashijima Jun, Yoshikawa Kozo, Nishioka Masanori, Sato Hirohiko, Iwata Tahashi, Shimada Mitsuo
Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.
Hepatogastroenterology. 2011 Mar-Apr;58(106):472-6.
BACKGROUND/AIMS: Barrett's esophagus is a major risk factor for esophageal adenocarcinoma. It is important to decide when and how to treat the patients with Barrett's esophagus (BE). It was reported that HDAC-1 (Histone Deacetylase-1) and MTA-1 (Metastasis-Associated Protein-1) were associated with initiation and progression of cancer. The aim of this study is to assess malignant potential of BE using the expression of HDAC-1 and MTA-1.
Seven BE cases with pathological specialized columnar epithelium and CK7/20 in an immunohistochemically positive state were selected from resected specimens of 23 patients with gastro-esophageal junction cancer. The expression of HDAC-1 and MTA-1 protein was evaluated using an immunohistochemical method.
All seven cases with Barrett's esophagus were diagnosed as low grade dysplasia. Positive expression of HDAC-1 and MTA-1 was found in 0 out of 7 cases (0%) with normal esophageal epithelium, and 0 out of 7 cases (0%) with normal gastric epithelium. On the other hand, positive expression of both HDAC-1 and MTA-1 was found in 6 out of 7 (85.7%) cases with Barrett's epithelium and 7 out of 7 (100%) cases with gastro-esophageal-junction-cancer, respectively.
Positive expression of HDAC-1 and MTA-1 was found even in low grade dysplasia. Therefore, BE with HDAC-1 and MTA-1 expression is considered to be a precancerous lesion re quiring curative treatment.
背景/目的：巴雷特食管是食管腺癌的主要危险因素。确定何时以及如何治疗巴雷特食管（BE）患者很重要。据报道，组蛋白去乙酰化酶-1（HDAC-1）和转移相关蛋白-1（MTA-1）与癌症的发生和进展有关。本研究的目的是利用HDAC-1和MTA-1的表达评估BE的恶性潜能。
从23例胃食管交界癌患者的切除标本中选取7例病理显示特殊柱状上皮且免疫组化CK7/20呈阳性状态的BE病例。采用免疫组化方法评估HDAC-1和MTA-1蛋白的表达。
所有7例巴雷特食管病例均被诊断为低级别异型增生。7例正常食管上皮病例中HDAC-1和MTA-1的阳性表达率为0（0%），7例正常胃上皮病例中HDAC-1和MTA-1的阳性表达率也为0（0%）。另一方面，7例巴雷特上皮病例中有6例（85.7%）HDAC-1和MTA-1均呈阳性表达，7例胃食管交界癌病例中HDAC-1和MTA-1均呈阳性表达的比例为7/7（100%）。
即使在低级别异型增生中也发现了HDAC-1和MTA-1的阳性表达。因此，伴有HDAC-1和MTA-1表达的BE被认为是需要根治性治疗的癌前病变。
